

9 November 2018 EMA/CVMP/722013/2018 Committee for Medicinal Products for Veterinary Use

Summary of opinion¹ (post-authorisation)

AFTOVAXPUR DOE

Common name:

Purified, inactivated foot and mouth disease virus, strain A turkey 14/98
Purified, inactivated foot and mouth disease virus, strain A22 Iraq /
Purified, inactivated foot and mouth disease virus, strain A24 Cruzeiro
Purified, inactivated foot and mouth disease virus, strain Asia1 Shamir
Purified, inactivated foot and mouth disease virus, strain O Taiwan 3/97
Purified, inactivated foot and mouth disease virus, strain O1 BFS
Purified, inactivated foot and mouth disease virus, strain O1 Manisa
Purified, inactivated foot and mouth disease virus, strain SAT2 Saudi Arabia

On 8 November 2018, the Committee for Medicinal Products for Veterinary Use (CVMP) adopted a positive opinion² recommending the granting of a variation to the terms of the marketing authorisation for the veterinary medicinal product AFTOVAXPUR DOE. The marketing authorisation holder for this veterinary medicinal product is MERIAL.

AFTOVAXPUR DOE is currently authorised as emulsion for injection for the active immunisation of cattle, sheep and pigs against foot-and-mouth disease to reduce clinical signs. The variation concerns the change of the onset of immunity in cattle and sheep.

Detailed conditions for the use of this product are described in the updated summary of product characteristics (SPC), for which an updated version reflecting the changes will be published in the revised European public assessment report (EPAR) and will be available in all official European Union languages after the variation to the marketing authorisation has been granted by the European Commission.

² Applicants may appeal any CVMP opinion, provided they notify the European Medicines Agency in writing of their intention to appeal within 15 days of receipt of the opinion.



¹ Summaries of opinion are published without prejudice to the Commission Decision.